Britain and America have announced a landmark bilateral deal that will guarantee zero levies on UK drug exports entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost expenditure on pharmaceuticals through the NHS. This move ensures that duties on these vital goods will remain at nothing for a period of three years.
This agreement comes after earlier statements to dramatically increase duties on patented drug products, with increases mentioned reaching one hundred percent.
"This arrangement with the Britain bolsters the international landscape for cutting-edge drugs and brings long-overdue fairness to transatlantic drug exports," an announcement declared.
Trade Impact
Medicines represent one of the the United Kingdom's most significant export categories to the America, which is clearly the biggest market for leading British pharmaceutical firms.
Trade data reveal that in the 12 months to the end of September, the UK sold pharmaceutical products valued at £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that span.
"This guarantee protects employment, increases funding and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary stated.
Key British Pledges
The pact involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to increase total health service expenditure on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The amount manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. Previously, rebates exceeded 20%.
Industry Background
The deal takes place against a long-running tension between the drug companies and the ministers over spending levels and NHS adoption.
This friction were heightened by claims that US consumers were charged several times more for the same drugs than people in the UK and Europe.
Recently, several significant drug company projects in the UK have been halted or cancelled, while major investments have been directed toward US facilities.
One official stated that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
